Retinoids in leukemia and cellular processes
Peer reviewed
Scollr summary
What this paper is about
This review summarizes current standard-of-care APL management, including risk stratification, induction, consolidation and maintenance strategies, and reviews emerging pharmacotherapeutic strategies, including oral arsenic formulations, tamibarotene, anti-CD33 antibody-based and cellular therapies, and other investigational agents.
Full abstract
Read the full abstract
INTRODUCTION: Acute promyelocytic leukemia (APL) has evolved from one of the most rapidly fatal neoplasms into the most curable acute myeloid leukemia subtype, following the sequential clinical introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Despite cure rates now approaching 100% in non-high-risk disease, early death occurring before or shortly after treatment initiation and relapse/refractory APL cases remain the principal obstacles to achieving a definitive cure. AREAS COVERED: This review summarizes current standard-of-care APL management, including risk stratification, induction, consolidation and maintenance strategies. It then reviews emerging pharmacotherapeutic strategies, including oral arsenic formulations, tamibarotene, anti-CD33 antibody-based and cellular therapies, and other investigational agents. A literature search of PubMed/MEDLINE was performed from the 1950s to 2026 using terms including 'acute promyelocytic leukemia,' 'ATRA,' 'arsenic trioxide,' 'oral arsenic,' 'tamibarotene,' 'gemtuzumab ozogamicin,'and other keywords, prioritizing recent randomized trials, prospective studies and expert consensus guidelines. EXPERT OPINION: Reducing early mortality through faster diagnostic suspicion, extending chemotherapy-free regimens to high-risk disease, and transitioning toward oral, outpatient-based arsenic formulations represent the most promising paths toward a cure. Tailored strategies for rare variant and resistant APL subtypes, including targeted triplet combinations represent a promising treatment for complex APL case, but warrant structured evaluation in prospective clinical trials.
Direct answer
What can I do from this paper page?
Use this page to scan "Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Retinoids in leukemia and cellular processes research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Propris2026Current,
title = {Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia},
author = {De Propris and Massimo Breccia and Federica Sisti and Alessandro Laganà and Emilia Scalzulli and Maria Laura Bisegna and Ida Carmosino and Costanza Andriola and Deborah Kasmi},
journal = {Expert Opinion on Pharmacotherapy},
year = {2026},
doi = {10.1080/14656566.2026.2749650},
url = {https://doi.org/10.1080/14656566.2026.2749650}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Retinoids in leukemia and cellular processes research papers?
Follow Retinoids in leukemia and cellular processes research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app